logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn injects first breast cancer patient with its flagship therapy

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr. Nader Pourhassan tells Proactive that biotech has injected its first patient, who has an aggressive type of breast cancer, with its leronlimab treatment.

Pourhassan explains the difference between this emergency investigational new drug (IND) circumstance versus its ongoing Phase 1b/2 clinical trial on leronlimab.

Quick facts: CytoDyn Inc.

Price: 3.1 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.49 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn continues to report strong results from COVID-19...

CytoDyn Inc (OTCQB: CYDY) President and CEO Nader Pourhassan and Bruce Patterson, M.D. and Chief Executive Officer and founder of IncellDx joined Steve Darling from Proactive Vancouver with news the company continues to see more impressive results from COVID-19 patients who have received...

3 weeks, 4 days ago

2 min read